Simpler Grants.gov #PAR-25-069

NIH Grant for Research on Incretin Mimetics and Cancer Risk Mechanisms

This opportunity from the National Institutes of Health (NIH) invites research grant applications focused on understanding how incretin mimetics—such as GLP-1, GIP-1, or dual GLP-1/GIP-1 agents—affect cancer risk. - Government Buyer: - National Institutes of Health (NIH) - Assistance Listing: 93.393 (Cancer Cause and Prevention Research) - OEMs and Vendors: - No specific OEMs or vendors are named, as this is a research grant opportunity - Products/Services Requested: - Research studies (preclinical and patient-based) investigating mechanisms by which incretin mimetics impact cancer risk - Focus on mechanistic understanding, not short-term outcomes like weight loss or diabetes - Unique or Notable Requirements: - Both clinical and laboratory-based research are eligible - No cost sharing or matching required - Wide eligibility: government, nonprofit, educational, business, and international organizations - No specific products, part numbers, or purchase quantities requested - Funding instrument is a grant, not a contract or purchase order

Description

This funding announcement aims to support preclinical and patient-based studies investigating the mechanisms by which incretin mimetics (including GLP-1, GIP-1, or dual GLP-1/GIP-1 agents) influence cancer risk. The focus is on understanding how these agents affect cancer risk rather than short-term outcomes like weight loss and diabetes. Current data suggest these agents may increase the risk of some obesity-related cancers while decreasing the risk of others. The announcement seeks to attract scientists to explore these dynamic changes and their implications for cancer risk.

View original listing